Sep 20, 2025
Dr. Khaja Shameem took part in the American Heart Association’s 5K Heart Walk. The event highlights the importance of community engagement in advancing cardiovascular health, complementing his ongoing research into the molecular mechanisms of heart disease.
Sep 19, 2025
In Press: Dr. Khaja Shameem’s review article, “Protein Phosphatases in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Mechanisms and Therapeutic Strategies” has been accepted for publication in Current Opinion in Physiology.
This review highlights the pivotal role of protein phosphatases in the pathogenesis of MASLD and MASH, focusing on their regulation of insulin signaling, lipid metabolism, inflammation, and fibrosis. It emphasizes how targeting phosphatase activity may offer new therapeutic opportunities to reduce steatosis, improve insulin sensitivity, and alleviate fibrosis, addressing a critical unmet need in liver disease treatment.
Aug 8, 2025
Dr. Khaja Shameem marked the conclusion of the 2025 SURF and AHA-SURE programs at HMRI, where he mentored undergraduate students.
Jun 16, 2025
Begining of SURF and AHA-SURE program at HMRI.
Feb 18, 2025
Dr. Khaja Shameem delivered the Bob Mackin Scientific Lecture at HMRI, presenting recent advances in cardiovascular research to a general public audience.
Jan 8, 2025
This website has gone live!
Increased PHLPP1 expression through ERK-4E-BP1 signaling axis drives nicotine induced oxidative stress related damage of cardiomyocytes.
Mohammed Abdul KS, Han K, Guerrero AB, Wilson CN, Kulkarni A, Purcell NH.
Journal of Molecular and Cellular Cardiology Aug 2024.
Cardioprotection by isosteviol derivate JC105: A unique drug property to activate ERK1/2 only when cells are exposed to hypoxia-reoxygenation.
Khaja Shameem Mohammed Abdul, Jayachandra Rayadurgam, Neha Faiz, Aleksandar Jovanović, Wen Tan.
Journal of Cellular and Molecular Medicine Aug 2020.